ArfGAP with GTPase domain, ankyrin repeat and PH domain 3Genealiases: AGAP-3 · CENTG3 · CRAG · MRIP-1 · cnt-g3
Q-omics provides the consensus-scored AGAP3 profile across patient tissues and cancer cell-line models. AGAP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, AGAP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, AGAP3 RNA expression shows 18,905 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, KIRC, and ACC as cancer lineages where AGAP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP3 survival associations across molecular data types. AGAP3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP3 RNA expression–survival associations across cancer types. High AGAP3 expression shows unfavorable associations in COAD, KIRC, ACC, KIRP, KICH and LIHC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for AGAP3 RNA expression.
This table summarizes AGAP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for AGAP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP3 shows higher tumor expression in KIRC, COAD, KIRP, HNSC, LIHC and STAD. The KIRC box plot shows higher AGAP3 RNA expression in tumor versus normal tissue (log2 FC = +1.136, t-test p < 0.001).
This table shows molecular features associated with AGAP3 in patient tissues and cancer cell lines. In patient samples, AGAP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
